RISK OF PSYCHOTIC SYMPTOMS FROM SUBSTANCE ABUSE IN THAILAND
Keywords:
Substance abuse, Psychotic symptom, Causal factors, ThailandAbstract
Substance abuse creates a burden of many diseases on drug users' physical and mental health. This case-control study aimed to compare the risk of developing psychotic symptoms from various substance abuse. The samples were drug users admitted to drug abuse clinics/psychiatric clinics in government hospitals aged 18 years and over across the country. A stratified multistage cluster sampling method was used to eligible 2,000 individuals. The samples were interviewed and observed by research assistants trained with researchers and healthcare professionals' history taking and physical examination. Statistical analysis utilized chi-square and multiple logistics regression.
The respondents were 94% male; most were over 24 years of age, 56% were single, 70% had graduated from junior high school and lower, and 27% unemployed. Factors affecting psychiatric symptoms consisted of 1) personal factors including marital status (single), and no occupation (unemployment, housework, no income), 2) drug factors such as yaba (methamphetamine tablet), ice (methamphetamine crystal), marijuana, heroin, volatile substances, ecstasy, ketamine, non-prescribed medicines, 3) duration of drug use (more than 10 years), and 4) regularly used (more than 20 days in 1 month), and frequently used (more than once a day). These factors statistically significantly increased 1-7 times the risk of developing psychiatric symptoms.
Downloads
References
Fine Art Department. The Sam Duang Act. Bangkok: Veteran Organisation Publishing; 1978. [in Thai].
Kanato M. Nunun W, Momem K. The Study of Drugs Policies. Khon Kean: ISAN KKU; 2010. [in Thai].
Office of the Narcotic Control Board. Drug Users Treatment Statistics in Thailand. Unpublished statistics; 2020. [in Thai].
Farrell M, Marsden J, Ali R, Ling, W. Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction 2002; 97: 771-772.
Kanato M, Leyatikul P, Wonguppa R. Size Estimation of Substances Users Population in Thailand 2019. ONCB Journal 2020; 36(2): 37-48.
Australian institute of criminology. National amphetamine type stimulant strategy: Bachground paper [online] 2007 [cited 202 Jan 5]. Available from: http://www.amphetamines.org.au/downloads/NationalATStrategyBackground.pdf
McCrady BS, Epstein EE. Addictions: A comprehensive guidebook. Oxford University Press; 2013.
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, Bevins RA. Methamphetamine-associated psychosis. Journal of Neuroimmune Pharmacology 2012; 7(1): 113-139.
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsychopharmacology 2003; 6(4): 347-352.
Gan H, Zhao Y, Jiang H, Zhu Y, Chen T, Tan H, Zhao M. A research of methamphetamine induced psychosis in 1,430 individuals with methamphetamine use disorder: Clinical features and possible risk factors. Frontiers in Psychiatry 2018; 9: 1-8.
Maneeganol S, Arunponpaisal S. Pimpanit V, Jarassaeng N, Boontoch K. Prevalence of Substance Use in Psychiatric Outpatient Clinic at Srinagarind Hospital. J Psychiatr Assoc Thailand 2014; 59(4): 371-380.
Dean K, Murray RM. Environmental risk factors for psychosis. Dialogues in clinical neuroscience 2005; 7(1): 69-80.
Tenn CC, Fletcher PJ, Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophrenia research 2003; 64(2-3): 103-114.
Barak S, Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 2007; 32(5): 989-999.
Chatterjee M, Ganguly S, Srivastava M, Palit G.Effect of ‘chronic’versus ‘acute’ketamine administration and its ‘withdrawal’effect on behavioural alterations in mice: implications for experimental psychosis. Behavioural brain research 2011; 216(1): 247-254.
Castañé A, Santana N, Artigas F. PCP -based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments. Psychopharmacology 2015; 2(21): 4085-4097.
Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD. Chronic LSD alters gene expression profiles in the mPF relevant to schizophrenia. Neuropharmacology 2014; 83: 1-8.
Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M. What can we learn about schizophrenia from studying the human model, drug‐induced psychosis?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2013; 162(7): 661-670.
Insel TR. Rethinking schizophrenia. Nature 2010; 468(7321): 187-193.
Jones CA, Watson DJG, Fone K. Animal models of schizophrenia. British journal of pharmacology 2011; 164(4): 1162-1194.
Schuckit MA. Alcohol-use disorders. The Lancet 2009; 373(9662): 492-501.
Ahmed S. Methods in Sample Surveys. [online] 2009 [cited 202 Jan 18]. Available from: http://ocw.jhsph. edu/courses/StatMethodsForSampleSurveys/PDFs/Lecture2.pdf.
Drug Commissioner of the German Federal Government. S3 Practice guideline methamphetamine-related disorders [online] 2009 [cited 2022 Jan 18]. Available from: https://www. aezq.de/mdb/edocs/pdf/literatur/s3-gl-methamphetamine-related disorders -long.pdf
National Drug Research Institute of the Australian Institute of Criminology. National amphetamine-type stimulant strategy background paper [online] 2007 [cited 2022 Jan 18]. Available from: https://www.yumpu.com/en/ document/read/22206335/national-amphetamine-type-stimulant-strategy- background-paper
UNODC. World Drug Report 2018. United Nations publication; 2018.
Arunogiri S, Foulds JA, McKetin R, Lubman DI. A systematic review of risk factors for methamphetamine-associated psychosis. Australian & New Zealand Journal of Psychiatry 2018; 52(6): 514-529.
McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA psychiatry 2013; 70(3), 319-324.
DiMiceli LE, Sherman SG, Aramrattana A, Sirirojn B. Celentano DD. Methamphetamine use is associated with high levels of depressive symptoms in adolescents and young adults in Rural Chiang Mai Province, Thailand. BMC public health 2016; 16(1): 1-9.
Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry 2010; 167(8): 987-993.
Degenhardt L, Saha S, Lim CC, Aguilar‐Gaxiola S, Al‐Hamzawi A, Alonso J, et al. The associations between psychotic experiences and substance use and substance use disorders: findings from the World Health Organization World Mental Health surveys. Addiction 2018; 113(5): 924-934.
Grant JE, Lust K, Chamberlain SR. Hallucinogen use is associated with mental health and addictive problems and impulsivity in university students. Addictive behaviors reports 2019; 10(2019): 1-7.
Swangpun K, Kanato M, Leyatikul P. The risk of drug abuse among preschool students in Phuket, Thailand. Iranian journal of public health 2019; 48(3): 451-457.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Community Health Development Quarterly Khon Kaen University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."
